Kigtropin je blagovna znamka za sintetično ustvarjenega človeka,Kigtropin je najboljši somatropin HGH na trgu, najučinkovitejši in najboljši rezultati, ki jih lahko oseba doseže, kigtropin je izdelan. Naročilo pošiljamo iz ZDA, chyna, in EU. Smo distributer za?kigtropin HGH veletrgovec? kigtropin HGH, Prosimo, dobite več kigtropina HGH Kitajska (celina) proizvajalci, izvozniki, dobavitelji, tovarne, Podjetja iz Kitajske .
Kigtropin je človeški rastni hormon (hGH) Somatropin, proizveden s tehnologijo rekombinantne DNK, ki je enaka HGH, ki ga telo naravno proizvaja.
Zaostajanje v rasti otrok zaradi endogenega pomanjkanja rastnega hormona (GHD).
Pri odraslih s pomanjkanjem rastnega hormona,KIGTROPIN zmanjšuje maščobno maso,poveča mišično maso in izboljša energijo,vitalnost in subjektivno dobro počutje. Pri bolnikih s hudimi opeklinami,Z aidsom povezana izguba mišic,ali na večjih operacijah,KIGTROPIN spodbuja celjenje ran,oslabi beljakovinsko-katabolični odziv in izboljša stanje dušika v celem telesu po operaciji.
Kigtropin comes as a freeze dried white powder – 10 x 10 IU (3.3 mg) vials per box. Like several others it started as a made up brand name which became popular due to good reviews in the bodybuilding community. It is manufactured by an unknown Chinese lab – which seems to be a common practice some Chinese companies use to avoid the HGH legality issues
In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 - 0.5 mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
In adults with adult-onset GHD, therapy should start with a low dose, 0.15 - 0.3 mg per day. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
In both cases treatment goal should be insulin-like growth factor (IGF-I) concentrations within 2 SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into the upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognized that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose rarely exceeds 1.0 mg per day. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 months. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.
Kigtropin for Elderly:
In patients above 60 years, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg per day.
How to Inject:
The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. Therefore, injection sites should be alternated.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
